A Phase 3 interventional study of Rotigotine in Restless Legs Syndrome, sponsored by UCB Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-25.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one has the largest enrollment, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 1st registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2005.
This study's enrollment of 811 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one has the largest enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2005, is one of 9 in phase 3, and was the 1st registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial.
The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine.
Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IRLS sum score and CGI Item 1 score severity of illness
Time frame: From Baseline at the end of the Maintenance Period
IRLS Responder: A responder is a subject with a decrease of ≥50% in IRLS sum score
Time frame: From Baseline at the end of the Maintenance Period
CGI Item 1 Responder: A responder is defined as a subject with a decrease of ≥50% in CGI Item 1
Time frame: From Baseline at the end of the Maintenance Period
Changes in CGI Items 2-3 (continuous) during the Maintenance Period; Change from Baseline in RLS-6 Rating Scales at the end of the Maintenance Period
The record gives a start of May 2005, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine